SPD 502 | CAS#254751-28-5 | antagonist

MedKoo Cat#: 584829 | Name: SPD 502

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SPD 502 is a potential selective AMPA antagonist for epilepsy.

Chemical Structure

SPD 502

CAS#254751-28-5

Theoretical Analysis

MedKoo Cat#: 584829

Name: SPD 502

CAS#: 254751-28-5

Chemical Formula: C24H28N4O7S

Exact Mass: 516.1679

Molecular Weight: 516.57

Elemental Analysis: C, 55.80; H, 5.46; N, 10.85; O, 21.68; S, 6.21

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

SPD 502; NS 1209; SPD502; NS1209; SPD-502; NS-1209;

IUPAC/Chemical Name

Butanoic acid, 2-(((5-(4-((dimethylamino)sulfonyl)phenyl)-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo(3,2-h)isoquinolin-3-ylidene)amino)oxy)-3-hydroxy-

InChi Key

HUFZQYCALCEHMB-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H28N4O7S/c1-13(29)22(24(31)32)35-26-21-18-11-17(14-5-7-15(8-6-14)36(33,34)27(2)3)16-9-10-28(4)12-19(16)20(18)25-23(21)30/h5-8,11,13,22,29H,9-10,12H2,1-4H3,(H,31,32)(H,25,26,30)

SMILES Code

CC(O)C(O/N=C(C1=C2C3=C(C(C4=CC=C(S(=O)(N(C)C)=O)C=C4)=C1)CCN(C)C3)\C(N2)=O)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 516.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia. 2009 Dec;50 Suppl 12:49-50. doi: 10.1111/j.1528-1167.2009.02366.x. Review. PubMed PMID: 19941524. 2: Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR. β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. Science. 2017 Sep 1;357(6354):891-898. doi: 10.1126/science.aaf3934. PubMed PMID: 28860381; PubMed Central PMCID: PMC5761666. 3: Keppel Hesselink JM. NS1209/SPD 502, A Novel Selective AMPA Antagonist for Stroke, Neuropathic Pain or Epilepsy? Drug Development Lessons Learned. Drug Dev Res. 2017 Mar;78(2):75-80. doi: 10.1002/ddr.21376. Epub 2017 Feb 13. PubMed PMID: 28195646. 4: Mula M. Emerging drugs for focal epilepsy. Expert Opin Emerg Drugs. 2013 Mar;18(1):87-95. doi: 10.1517/14728214.2013.750294. Epub 2012 Nov 26. Review. PubMed PMID: 23176519. 5: A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group. Eur Heart J. 1997 Sep;18(9):1416-25. PubMed PMID: 9458447. 6: Bin Sayeed MS, Shams T, Fahim Hossain S, Rahman MR, Mostofa A, Fahim Kadir M, Mahmood S, Asaduzzaman M. Nigella sativa L. seeds modulate mood, anxiety and cognition in healthy adolescent males. J Ethnopharmacol. 2014 Feb 27;152(1):156-62. doi: 10.1016/j.jep.2013.12.050. Epub 2014 Jan 8. PubMed PMID: 24412554. 7: Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, Breteler MM; CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010 May 12;303(18):1832-40. doi: 10.1001/jama.2010.574. PubMed PMID: 20460622; PubMed Central PMCID: PMC2989531. 8: Keeler L, Kirby RL, Parker K, McLean KD, Hayden JA. Effectiveness of the Wheelchair Skills Training Program: a systematic review and meta-analysis(). Disabil Rehabil Assist Technol. 2018 Apr 4:1-19. doi: 10.1080/17483107.2018.1456566. [Epub ahead of print] PubMed PMID: 29616832. 9: Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem. 2008 Feb 14;2:21-39. PubMed PMID: 19787095; PubMed Central PMCID: PMC2746576. 10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PubMed PMID: 15071612. 11: Krause JS, Zhai Y, Saunders LL, Carter RE. Risk of mortality after spinal cord injury: an 8-year prospective study. Arch Phys Med Rehabil. 2009 Oct;90(10):1708-15. doi: 10.1016/j.apmr.2009.04.020. PubMed PMID: 19801060; PubMed Central PMCID: PMC3181069. 12: Schmitt CP, Ardissino G, Testa S, Claris-Appiani A, Mehls O. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol. 2003 May;18(5):440-4. Epub 2003 Apr 8. PubMed PMID: 12687466. 13: Krause JS, Saunders LL, Zhai Y. Stability of predictors of mortality after spinal cord injury. Spinal Cord. 2012 Apr;50(4):281-4. doi: 10.1038/sc.2011.158. Epub 2012 Jan 10. PubMed PMID: 22231541; PubMed Central PMCID: PMC3321101. 14: Dhingra RC, Wyndham C, Bauernfeind R, Denes P, Wu D, Swiryn S, Rosen KM. Significance of chronic bifascicular block without apparent organic heart disease. Circulation. 1979 Jul;60(1):33-9. PubMed PMID: 445730. 15: Pai RG, Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin Cardiol. 2007 Jul;30(7):349-54. PubMed PMID: 17674374. 16: Chen CF, Drew KL. Droplet-based microdialysis-Concept, theory, and design considerations. J Chromatogr A. 2008 Oct 31;1209(1-2):29-36. doi: 10.1016/j.chroma.2008.09.006. Epub 2008 Sep 7. PubMed PMID: 18814875; PubMed Central PMCID: PMC3796385. 17: Grossman SH. An equilibrium study of the dependence of secondary and tertiary structure of creatine kinase on subunit association. Biochim Biophys Acta. 1994 Nov 16;1209(1):19-23. PubMed PMID: 7947978. 18: Wiersinga WM, Chopra IJ, Solomon DH. Specific nuclear binding sites of triiodothyronine and reverse triiodothyronine in rat and pork liver: similarities and discrepancies. Endocrinology. 1982 Jun;110(6):2052-8. PubMed PMID: 7075548.